327
Participants
Start Date
August 25, 2021
Primary Completion Date
September 26, 2023
Study Completion Date
September 26, 2023
Guselkumab
Guselkumab 100 mg will be administered as a SC injection.
Placebo
Matching placebo will be administered as a SC injection.
Peking University Third Hospital, Beijing
Beijing Tongren Hospital, CMU, Beijing
Shanghai Ruijin Hospital, Shanghai
Huashan Hospital Fudan University, Shanghai
Shanghai skin disease hospital, Shanghai
Jiangsu Province Hospital, Nanjing
Hospital of Dermatology, Chinese Academy of Medical Science, Nanjing
The 1st affiliated hospital of Anhui Medical University, Hefei
Skin Disease Hospital of Shandong Province, Jinan
Tianjin Medical University General Hospital, Tianjin
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin
Zhejiang Provincial People's Hospital, Hangzhou
The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Fujian Medical University, Fuzhou
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing
Xiangya Hospital Central South University, Changsha
The second Xiangya Hospital of Central South University, Changsha
Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Henan province people's hospital, Zhengzhou
Dermatology Hospital of Southern Medical University, Guangzhou
University of Hong Kong-Shenzhen Hospital, Shenzhen
West China Hospital,Sichuan University, Chengdu
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Janssen Research & Development, LLC
INDUSTRY